B7-H3-mediated deubiquitination stabilizing CYP1B1 expression promotes chemotherapy resistance in colorectal cancer

被引：0
作者：
Liu, Huan [2 ]
Li, Guifang [2 ]
Shen, Chenjie [2 ]
Qi, Xiaowei [4 ]
Liu, Yankui [4 ]
Hua, Dong [5 ]
Mao, Yong [2 ]
Zhang, Ting [1 ,3 ]
机构：
[1] Jiangnan Univ, Affiliated Hosp, Inst Canc, Wuxi 214062, Jiangsu, Peoples R China
[2] Jiangnan Univ, Affiliated Hosp, Dept Oncol, Wuxi 214062, Jiangsu, Peoples R China
[3] Univ Plymouth, Fac Hlth, Peninsula Med Sch, Plymouth PL6 8BU, Devon, England
[4] Jiangnan Univ, Dept Pathol, Affiliated Hosp, Wuxi 214062, Jiangsu, Peoples R China
[5] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Wuxi, Peoples R China
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2025年 / 1871卷 / 05期
关键词：
CRC; B7-H3; Chemotherapy resistance; Ubiquitination; B7-H3; PROMOTES; CELLS; METABOLISM; MECHANISM;
D O I：
10.1016/j.bbadis.2025.167771
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. It is frequently characterized by chemotherapy resistance,which is a predominant factor contributing to unfavorable patient prognosis. B7-H3 is a novel tumor marker and a potential immunotherapy target. High B7-H3 expression in colorectal cancer is associated with adverse prognosis. In this study, we noted increased B7-H3 expression in colorectal cancer tumor tissues. Both in vivo and in vitro experiments demonstrated that increased B7-H3 expression promotes resistance to chemotherapy in CRC. Furthermore, our findings suggest that B7-H3 mediates CRC resistance by modulating CYP1B1 expression. Mechanistic investigations indicated that B7-H3 inhibited the ubiquitination of CYP1B1, stabilized its expression,and consequently enhanced chemotherapeutic resistance in CRC. In summary, our results underscore the significance of the B7-H3-CYP1B1 interaction as a crucial therapeutic target for overcoming chemotherapy resistance in CRC.
引用
收藏
页数：12
相关论文
共 37 条
  • [1] Sung H., Ferlay J., Siegel R.L., Laversanne M., Et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 3, pp. 209-249, (2021)
  • [2] Araghi M., Soerjomataram I., Jenkins M., Brierley J., Et al., Global trends in colorectal cancer mortality: projections to the year 2035, Int. J. Cancer, 144, 12, pp. 2992-3000, (2019)
  • [3] Holch J.W., Demmer M., Lamersdorf C., Michl M., Et al., Pattern and dynamics of distant metastases in metastatic colorectal Cancer, Visc Med., 33, 1, pp. 70-75, (2017)
  • [4] Siegel R.L., Miller K.D., Fedewa S.A., Ahnen D.J., Et al., Colorectal cancer statistics, 2017, CA Cancer J. Clin., 67, 3, pp. 177-193, (2017)
  • [5] Wang S., Mou J., Cui L., Wang X., Zhang Z., Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3, Biomed. Pharmacother., 102, pp. 1037-1044, (2018)
  • [6] Hu X., Xu M., Hu Y., Li N., Zhou L., B7-H3, negatively regulated by miR-128, promotes colorectal Cancer cell proliferation and migration, Cell Biochem. Biophys., 79, 2, pp. 397-405, (2021)
  • [7] Yu T.T., Zhang T., Lu X., Wang R.Z., B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma, Onco. Targets Ther., 11, pp. 4693-4700, (2018)
  • [8] Liu Z., Zhang W., Phillips J.B., Arora R., Et al., Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation, Oncogene, 38, 1, pp. 88-102, (2019)
  • [9] Zhong C., Tao B., Chen Y., Guo Z., Et al., 13
  • [10] Kang F., Wang L., Jia H., Li D., Et al., Correction to: B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/slug signaling pathway, Cancer Cell Int., 21, 1, (2021)
1234